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Background
Glycemic control is critical for in-patients and dysglyce-
mia is associated with worse prognosis and higher mor-
tality. Insulin therapy is considered the best treatment
on this scenario and basal insulin analogues, such as
insulin glargine (IGlar) and IDeg, could be useful
options, however there are no studies comparing IGlar
and IDeg evaluating glucose variability (GV) in hospita-
lized patients, neither the transition between them.
Objective
To present a case series describing the efficacy and
safety of IDeg in-patientes with diabetes using GV and
rate of hypoglycemia when compared with IGlar.
Materials and methods
Retrospective analysis of blood glucose obtained with
point-of-care testing of 10 diabetic patients admitted at
Bandeirantes Hospital, Sao Paulo, between October
2014 and April 2015, previously treated with IGlar for a
minimum of 7 days and switched to IDeg for at least 7
days more during hospitalization. Parameters studied
included GV, standard deviation (SD), coefficient of var-
iation (CV) and mean glucose levels, obtained from soft-
ware PXP Abbott. Hypoglycemia was defined as blood
glucose (BG) <70mg/dL and it was severe if BG <40mg/
dL. Basal insulin dose was compared on the last day of
both, after achievement of steady state.
Results
3/10 patients had type 1 diabetes mellitus (T1D) for
over 10 yrs., previous treatment with insulin therapy in
a basal-bolus regimen. Average age was 46 yrs. and
mean HbA1c was 9% and no benefit could be noticed.
7/10 patients had type 2 diabetes mellitus (T2D), with
duration of >10 yrs., the majority had previous insulin
treatment. Mean age was 70 yrs. and mean HbA1c was
9,7%. All T2D patients maintained CV, and 57% had a
reduction in SD, improving GV. Basal insulin dose with
IDeg was lower at discharge as compared to IGlar in
T2D. Severe hypoglycemia events were diminished after
switching (see Figure 1).
Conclusions
In this report, GV was lower in T2D patients treated
with IDeg as compared to IGlar, although the same
could not be seen in T1D, perhaps due to the small
number of patients included. More studies in this popu-
lation are needed to confirm this hypothesis and contin-
uous glucose monitoring should be preferred. IDeg
proved to be a safe and effective alternative at hospital
and might improve GV. This would be better due to its
predictability of effect and low rate of hypoglycemia,
important among hospitalized patients.
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Figure 1 Summary of results
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